Investor Presentaiton
116
Investor presentation Full year 2022
EMEA at a glance
EMEA
Million
300
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
25%
120
Full year 2022
Sales
(mDKK)
Growth²
120%
Total GLP-13
14,855
43%
I
19%
I
I
I
200
I
Long-acting insulin4
7,157
4%
GLP-1
90
90%
Premix insulin5
2,622
-13%
35.22%¹
Fast-acting insulin
6,456
-2%
I
100
60
260
195
158
60
3.14%1
Insulin
60%
Human insulin
1,983
-10%
Total insulin
18,218
-3%
30
30
OAD
30%
Other Diabetes care?
717
-2%
12.45%¹
Diabetes care
33,790
13%
0
2021
0
0%
Obesity care8
3,615
96%
2030
2045
Nov
2017
Nov
2022
Diabetes & Obesity
37,405
18%
care
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
Rare disease⁹
6,831
-1%
Total
44,236
15%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
Nov 2022: Novo Nordisk 48%, Sanofi 32% and Eli Lilly 16%; Competitor GLP-1
value market shares, as of Nov 2022: Novo Nordisk 61%, Eli Lilly 38% and
AstraZeneca 2%; OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT,
Nov 2022 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises RyzodegⓇ and
NovoMixⓇ: 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®; 9 Comprises
primarily NovoSeven®, Novo Eight® NovoThirteen®, Esperoct®, RefixiaⓇ,
Norditropin, Vagifem® and Activelle®View entire presentation